Phase 1 × Myeloproliferative Disorders × Etoposide × Clear all
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00006040 2013-06-19

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00004904 2012-06-04

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed
NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled
NCT00003243 2010-03-10

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed